Ajit Bharti Ji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1424015/publications.pdf

Version: 2024-02-01

28 papers

2,395 citations

331670 21 h-index 25 g-index

28 all docs 28 docs citations

28 times ranked

3047 citing authors

#	Article	IF	CITATIONS
1	Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nature Chemical Biology, $2005,1,290-297.$	8.0	458
2	Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene, 2000, 19, 1975-1981.	5.9	284
3	Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature, 1997, 386, 732-735.	27.8	259
4	Inactivation of DNA-Dependent Protein Kinase by Protein Kinase Cl´: Implications for Apoptosis. Molecular and Cellular Biology, 1998, 18, 6719-6728.	2.3	205
5	Jade-1 inhibits Wnt signalling by ubiquitylating \hat{l}^2 -catenin and mediates Wnt pathway inhibition by pVHL. Nature Cell Biology, 2008, 10, 1208-1216.	10.3	162
6	Induction of heat shock proteins by heregulin \hat{l}^21 leads to protection from apoptosis and anchorage-independent growth. Oncogene, 2005, 24, 6564-6573.	5.9	107
7	p73Î ² Is Regulated by Protein Kinase Cδ Catalytic Fragment Generated in the Apoptotic Response to DNA Damage. Journal of Biological Chemistry, 2002, 277, 33758-33765.	3.4	106
8	Titin Determines the Frank-Starling Relation in Early Diastole. Journal of General Physiology, 2003, 121, 97-110.	1.9	94
9	Targeting of the c-Abl Tyrosine Kinase to Mitochondria in the Necrotic Cell Death Response to Oxidative Stress. Journal of Biological Chemistry, 2001, 276, 17281-17285.	3.4	93
10	Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Research, 2004, 24, 1031-8.	1.1	73
11	Protein Kinase A Binds and Activates Heat Shock Factor 1. PLoS ONE, 2010, 5, e13830.	2.5	64
12	Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in Myocytes. Journal of Biological Chemistry, 2005, 280, 13148-13152.	3.4	62
13	Biomarker discovery in lung cancer—promises and challenges of clinical proteomics. Mass Spectrometry Reviews, 2007, 26, 451-466.	5.4	58
14	Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight, 2018, 3, .	5.0	52
15	A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol. Proceedings of the National Academy of Sciences of the United States of America, 2005, $102, 15635-15640$.	7.1	50
16	Silencing the <i>hsp25</i> Gene Eliminates Migration Capability of the Highly Metastatic Murine 4T1 Breast Adenocarcinoma Cell. Tumor Biology, 2006, 27, 17-26.	1.8	50
17	Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS ONE, 2015, 10, e0135156.	2.5	47
18	COPI coatomer complex proteins facilitate the translocation of anthrax lethal factor across vesicular membranes <i>in vitro </i> i). Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5254-5259.	7.1	35

#	Article	IF	CITATIONS
19	Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Research, 2003, 23, 49-62.	1.1	28
20	Phosphorylation of DNA Topoisomerase I by the c-Abl Tyrosine Kinase Confers Camptothecin Sensitivity. Journal of Biological Chemistry, 2004, 279, 51851-51861.	3.4	25
21	Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer. Current Proteomics, 2010, 7, 49-56.	0.3	23
22	GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) <i>in vivo</i> and functions as an unfoldase <i>in vitro</i> . Molecular Microbiology, 2011, 81, 1390-1401.	2.5	20
23	ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Biochemical and Biophysical Research Communications, 2012, 418, 116-121.	2.1	20
24	Modulation of c-Kit/SCF Pathway Leads to Alterations in Topoisomerase-I Activity in Small Cell Lung Cancer. Journal of Environmental Pathology, Toxicology and Oncology, 2004, 23, 16.	1.2	17
25	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clinical Colorectal Cancer, 2021, 20, e129-e138.	2.3	2
26	HSF1: An Emerging Factor In Cancer. , 2007, , 53-72.		1
27	Effect of DNA-PK dependent phosphorylation of topo-I-S10 on its rate of proteasomal degradation and CPT response Journal of Clinical Oncology, 2015, 33, 606-606.	1.6	0
28	IHC-based predictive biomarker for irinotecan response Journal of Clinical Oncology, 2016, 34, 548-548.	1.6	0